42 results on '"Geiser K"'
Search Results
2. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial
- Author
-
de Botton, Stéphane, Chevret, Sylvie, Sanz, Miguel, Dombret, Hervé, Thomas, Xavier, Guerci, Agnès, Fey, Martin, Rayon, Consuelo, Huguet, Françoise, Sotto, Jean-Jacques, Gardin, Claude, Cony Makhoul, Pascale, Travade, Philippe, Solary, Eric, Fegueux, Nathalie, Bordessoule, Dominique, San Miguel, Jesus, Link, Harmut, Desablens, Bernard, Stamatoullas, Aspasia, Deconinck, Eric, Geiser, K, Hess, U, Maloisel, Fréderic, Castaigne, Sylvie, Preudhomme, Claude, Chomienne, Christine, Degos, Laurent, and Fenaux, Pierre
- Published
- 2000
3. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
- Author
-
Parmar MKB, Torri V, Bonaventura A, Bonazzi C, Colombo N, Delaloye JF, Marsoni S, Mangioni C, Sandercock J, Sessa C, Williams C, Tinazzi A, Flann M, Geiser K, Scorpiglione N, Stewart JF, Chaves J, Palmeiro E, Curtain A, McCormack T, Gennatas C, Marras F, Oppo TG, Balestrino M, Malzoni C, Malzoni M, Belli M, Geminiani ML, Crestani G, Monaco A, Vavala V, Piatto E, Barattini G, Fornara PG, Chetri MC, Santeufemia G, Artioli F, Carone D, Fanizza G, Trentadue R, Priolo D, Scollo P, Nigro SC, Petrina M, Mastrantonio P, Spanna GD, Zagni R, Belloni C, Colleoni R, Redaelli L, Cavagnini A, Di Costanzo G, Perroni D, Arienti S, Orfanotti G, Cantoni FM, Secli R, Bianchi A, Martinello R, Mollica G, Maizzi D, Picchiarelli ME, Fiorini G, Borsani M, Colombo E, Garsia S, Melgrati L, Paggi G, Brunenghi GM, Casini M, Isa L, Algeri R, Prozio G, Belfiore G, Angelini F, D'Aprile M, Moreschi M, Mauri ML, Natale N, Senzani FM, Pavanato G, Poggi G, Garuti G, Luerti M, Cruciani G, Pagano F, Baccolo M, Poddi ER, Bocciolone L, Sabelli MA, Maggi R, Restelli C, D'Antona A, Locatelli MC, Pessi A, Raina A, Chiari S, Gabriele A, Pittelli MR, Iacobelli P, Dogliotti L, Gorzegno G, Musso P, Vegna G, Coco G, Alletti DG, Picciotto F, Lucchese V, Epis A, di Palumbo VS, Drudi G, Ravaioli A, Zampella D, Morandi MG, Gorga G, Zucchelli C, Cariello S, Galletto L, Sussio M, Massacesi L, Massacesi M, Carli A, Tucci E, Tajani E, Corrado G, Bumma S, Durando A, Massobrio M, Sberveglieri M, Biasio M, Guercio E, Jura R, Danese S, Wierdis T, Farnelli C, Tarantino G, Grassi R, Repetti F, Rocchi B, Grampa M, Ercoli A, Griso C, Signori E, Zanini L, Presti M, Klimek M, Urbanski K, Biswas A, Viegas O, Kochli O, Dreher E, Fey M, Beck G, Ludin J, Bonnefoi H, Krauer F, Bauer J, Delmore G, Furrer C, Lorenz U, Thurlimann B, Bronz L, Sanna P, Wyss D, Goldhirsch A, Gyr T, Leidi L, Pastorelli G, Pagani O, Rey P, Hailer U, Benz J, Kaye SB, Reed NS, Symonds RP, Atkinson RJ, Axford AT, Rustin G, Seckl MJ, Green JA, Scott IV, Guthrie D, Harper PG, Calman F, Dobbs HJ, Weir P, Cassoni A, Lederman JA, Souhami RL, Bozzino J, Adab F, Redman CWE, Scoble JE, Paterson M, Daniel F, Cowley N, Williams CJ, Spooner D, Hong A, McIllmurray M, Hendy-Ibbs P, Hall V, Iveson TJ, Whitehouse JMA, Garry R, Lamont A, Robinson A, Trask CW, Clubb AW, Murrell D, Newman G, Wilkins M, Goldthorp WO, Roberts JK, Radstone DJ, Whipp MJ, Ledermann JA, Pater J, Buyse M, Omura G, Parmar, Mkb, Torri, V, Bonaventura, A, Bonazzi, C, Colombo, N, Delaloye, Jf, Marsoni, S, Mangioni, C, Sandercock, J, Sessa, C, Williams, C, Tinazzi, A, Flann, M, Geiser, K, Scorpiglione, N, Stewart, Jf, Chaves, J, Palmeiro, E, Curtain, A, Mccormack, T, Gennatas, C, Marras, F, Oppo, Tg, Balestrino, M, Malzoni, C, Malzoni, M, Belli, M, Geminiani, Ml, Crestani, G, Monaco, A, Vavala, V, Piatto, E, Barattini, G, Fornara, Pg, Chetri, Mc, Santeufemia, G, Artioli, F, Carone, D, Fanizza, G, Trentadue, R, Priolo, D, Scollo, P, Nigro, Sc, Petrina, M, Mastrantonio, P, Spanna, Gd, Zagni, R, Belloni, C, Colleoni, R, Redaelli, L, Cavagnini, A, Di Costanzo, G, Perroni, D, Arienti, S, Orfanotti, G, Cantoni, Fm, Secli, R, Bianchi, A, Martinello, R, Mollica, G, Maizzi, D, Picchiarelli, Me, Fiorini, G, Borsani, M, Colombo, E, Garsia, S, Melgrati, L, Paggi, G, Brunenghi, Gm, Casini, M, Isa, L, Algeri, R, Prozio, G, Belfiore, G, Angelini, F, D'Aprile, M, Moreschi, M, Mauri, Ml, Natale, N, Senzani, Fm, Pavanato, G, Poggi, G, Garuti, G, Luerti, M, Cruciani, G, Pagano, F, Baccolo, M, Poddi, Er, Bocciolone, L, Sabelli, Ma, Maggi, R, Restelli, C, D'Antona, A, Locatelli, Mc, Pessi, A, Raina, A, Chiari, S, Gabriele, A, Pittelli, Mr, Iacobelli, P, Dogliotti, L, Gorzegno, G, Musso, P, Vegna, G, Coco, G, Alletti, Dg, Picciotto, F, Lucchese, V, Epis, A, di Palumbo, V, Drudi, G, Ravaioli, A, Zampella, D, Morandi, Mg, Gorga, G, Zucchelli, C, Cariello, S, Galletto, L, Sussio, M, Massacesi, L, Massacesi, M, Carli, A, Tucci, E, Tajani, E, Corrado, G, Bumma, S, Durando, A, Massobrio, M, Sberveglieri, M, Biasio, M, Guercio, E, Jura, R, Danese, S, Wierdis, T, Farnelli, C, Tarantino, G, Grassi, R, Repetti, F, Rocchi, B, Grampa, M, Ercoli, A, Griso, C, Signori, E, Zanini, L, Presti, M, Klimek, M, Urbanski, K, Biswas, A, Viegas, O, Kochli, O, Dreher, E, Fey, M, Beck, G, Ludin, J, Bonnefoi, H, Krauer, F, Bauer, J, Delmore, G, Furrer, C, Lorenz, U, Thurlimann, B, Bronz, L, Sanna, P, Wyss, D, Goldhirsch, A, Gyr, T, Leidi, L, Pastorelli, G, Pagani, O, Rey, P, Hailer, U, Benz, J, Kaye, Sb, Reed, N, Symonds, Rp, Atkinson, Rj, Axford, At, Rustin, G, Seckl, Mj, Green, Ja, Scott, Iv, Guthrie, D, Harper, Pg, Calman, F, Dobbs, Hj, Weir, P, Cassoni, A, Lederman, Ja, Souhami, Rl, Bozzino, J, Adab, F, Redman, Cwe, Scoble, Je, Paterson, M, Daniel, F, Cowley, N, Williams, Cj, Spooner, D, Hong, A, Mcillmurray, M, Hendy-Ibbs, P, Hall, V, Iveson, Tj, Whitehouse, Jma, Garry, R, Lamont, A, Robinson, A, Trask, Cw, Clubb, Aw, Murrell, D, Newman, G, Wilkins, M, Goldthorp, Wo, Roberts, Jk, Radstone, Dj, Whipp, Mj, Ledermann, Ja, Pater, J, Buyse, M, and Omura, G
- Published
- 1998
4. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study
- Author
-
Parmar, MKB, Torri, V, Bonaventura, A, Bonazzi, C, Delaloye, J, Marsoni, S, Mangioni, C, Sandercock, J, Sessa, C, Williams, C, Tinazzi, A, Flann, M, Geiser, K, Scorpiglione, N, Stewart, J, Chaves, J, Palmeiro, E, Curtain, A, McCormack, T, Gennatas, C, Marras, F, Oppo, T, Balestrino, M, Malzoni, C, Malzoni, M, Belli, M, Geminiani, M, Crestani, G, Monaco, A, Vavala, V, Piatto, E, Barattini, G, Fornara, P, Chetri, M, Santeufemia, G, Artioli, F, Carone, D, Fanizza, G, Trentadue, R, Priolo, D, Scollo, P, Nigro, S, Petrina, M, Mastrantonio, P, Spanna, G, Zagni, R, Belloni, C, Colleoni, R, Redaelli, L, Cavagnini, A, Di Costanzo, G, Perroni, D, Arienti, S, Orfanotti, G, Cantoni, F, Secli, R, Bianchi, A, Martinello, R, Mollica, G, Maizzi, D, Picchiarelli, M, Fiorini, G, Borsani, M, Colombo, E, Garsia, S, Melgrati, L, Paggi, G, Brunenghi, G, Casini, M, Isa, L, Algeri, R, Prozio, G, Belfiore, G, Angelini, F, D'Aprile, M, Moreschi, M, Mauri, M, Natale, N, Senzani, F, Pavanato, G, Poggi, G, Garuti, G, Luerti, M, Cruciani, G, Pagano, F, Baccolo, M, Poddi, E, Bocciolone, L, Sabelli, M, Maggi, R, Restelli, C, D'Antona, A, Locatelli, M, Pessi, A, Raina, A, Chiari, S, Gabriele, A, Pittelli, M, Iacobelli, P, Dogliotti, L, Gorzegno, G, Musso, P, Vegna, G, Coco, G, Alletti, D, Picciotto, F, Lucchese, V, Epis, A, di Palumbo, V, Drudi, G, Ravaioli, A, Zampella, D, Morandi, M, Gorga, G, Zucchelli, C, Cariello, S, Galletto, L, Sussio, M, Massacesi, L, Massacesi, M, Carli, A, Tucci, E, Tajani, E, Corrado, G, Bumma, S, Durando, A, Massobrio, M, Sberveglieri, M, Biasio, M, Guercio, E, Jura, R, Danese, S, Wierdis, T, Farnelli, C, Tarantino, G, Grassi, R, Repetti, F, Rocchi, B, Grampa, M, Ercoli, A, Griso, C, Signori, E, Zanini, L, Presti, M, Klimek, M, Urbanski, K, Biswas, A, Viegas, O, Kochli, O, Dreher, E, Fey, M, Beck, G, Ludin, J, Bonnefoi, H, Krauer, F, Bauer, J, Delmore, G, Furrer, C, Lorenz, U, Thurlimann, B, Bronz, L, Sanna, P, Wyss, D, Goldhirsch, A, Gyr, T, Leidi, L, Pastorelli, G, Pagani, O, Rey, P, Hailer, U, Benz, J, Kaye, S, Reed, N, Symonds, R, Atkinson, R, Axford, A, Rustin, G, Seckl, M, Green, J, Scott, I, Guthrie, D, Harper, P, Calman, F, Dobbs, H, Weir, P, Cassoni, A, Lederman, J, Souhami, R, Bozzino, J, Adab, F, Redman, C, Scoble, J, Paterson, M, Daniel, F, Cowley, N, Spooner, D, Hong, A, McIllmurray, M, Hendy Ibbs, P, Hall, V, Iveson, T, Whitehouse, J, Garry, R, Lamont, A, Robinson, A, Trask, C, Clubb, A, Murrell, D, Newman, G, Wilkins, M, Goldthorp, W, Roberts, J, Radstone, D, Whipp, M, Ledermann, J, Pater, J, Buyse, M, Omura, G., COLOMBO, NICOLETTA, Parmar, M, Torri, V, Bonaventura, A, Bonazzi, C, Colombo, N, Delaloye, J, Marsoni, S, Mangioni, C, Sandercock, J, Sessa, C, Williams, C, Tinazzi, A, Flann, M, Geiser, K, Scorpiglione, N, Stewart, J, Chaves, J, Palmeiro, E, Curtain, A, Mccormack, T, Gennatas, C, Marras, F, Oppo, T, Balestrino, M, Malzoni, C, Malzoni, M, Belli, M, Geminiani, M, Crestani, G, Monaco, A, Vavala, V, Piatto, E, Barattini, G, Fornara, P, Chetri, M, Santeufemia, G, Artioli, F, Carone, D, Fanizza, G, Trentadue, R, Priolo, D, Scollo, P, Nigro, S, Petrina, M, Mastrantonio, P, Spanna, G, Zagni, R, Belloni, C, Colleoni, R, Redaelli, L, Cavagnini, A, Di Costanzo, G, Perroni, D, Arienti, S, Orfanotti, G, Cantoni, F, Secli, R, Bianchi, A, Martinello, R, Mollica, G, Maizzi, D, Picchiarelli, M, Fiorini, G, Borsani, M, Colombo, E, Garsia, S, Melgrati, L, Paggi, G, Brunenghi, G, Casini, M, Isa, L, Algeri, R, Prozio, G, Belfiore, G, Angelini, F, D'Aprile, M, Moreschi, M, Mauri, M, Natale, N, Senzani, F, Pavanato, G, Poggi, G, Garuti, G, Luerti, M, Cruciani, G, Pagano, F, Baccolo, M, Poddi, E, Bocciolone, L, Sabelli, M, Maggi, R, Restelli, C, D'Antona, A, Locatelli, M, Pessi, A, Raina, A, Chiari, S, Gabriele, A, Pittelli, M, Iacobelli, P, Dogliotti, L, Gorzegno, G, Musso, P, Vegna, G, Coco, G, Alletti, D, Picciotto, F, Lucchese, V, Epis, A, di Palumbo, V, Drudi, G, Ravaioli, A, Zampella, D, Morandi, M, Gorga, G, Zucchelli, C, Cariello, S, Galletto, L, Sussio, M, Massacesi, L, Massacesi, M, Carli, A, Tucci, E, Tajani, E, Corrado, G, Bumma, S, Durando, A, Massobrio, M, Sberveglieri, M, Biasio, M, Guercio, E, Jura, R, Danese, S, Wierdis, T, Farnelli, C, Tarantino, G, Grassi, R, Repetti, F, Rocchi, B, Grampa, M, Ercoli, A, Griso, C, Signori, E, Zanini, L, Presti, M, Klimek, M, Urbanski, K, Biswas, A, Viegas, O, Kochli, O, Dreher, E, Fey, M, Beck, G, Ludin, J, Bonnefoi, H, Krauer, F, Bauer, J, Delmore, G, Furrer, C, Lorenz, U, Thurlimann, B, Bronz, L, Sanna, P, Wyss, D, Goldhirsch, A, Gyr, T, Leidi, L, Pastorelli, G, Pagani, O, Rey, P, Hailer, U, Benz, J, Kaye, S, Reed, N, Symonds, R, Atkinson, R, Axford, A, Rustin, G, Seckl, M, Green, J, Scott, I, Guthrie, D, Harper, P, Calman, F, Dobbs, H, Weir, P, Cassoni, A, Lederman, J, Souhami, R, Bozzino, J, Adab, F, Redman, C, Scoble, J, Paterson, M, Daniel, F, Cowley, N, Spooner, D, Hong, A, Mcillmurray, M, Hendy Ibbs, P, Hall, V, Iveson, T, Whitehouse, J, Garry, R, Lamont, A, Robinson, A, Trask, C, Clubb, A, Murrell, D, Newman, G, Wilkins, M, Goldthorp, W, Roberts, J, Radstone, D, Whipp, M, Ledermann, J, Pater, J, Buyse, M, and Omura, G
- Subjects
Antineoplastic Combined Chemotherapy Protocol ,Ovarian Neoplasm ,Alopecia ,Leukopenia ,Middle Aged ,Thrombocytopenia ,Carboplatin ,Antineoplastic Agent ,Doxorubicin ,Proportional Hazards Model ,Female ,Survival Analysi ,Cisplatin ,Cyclophosphamide ,Aged ,Human - Abstract
A series of meta-analyses of randomised controlled trials raised the question of whether the three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) was more or less effective than optimal-dose single-agent carboplatin for women with advanced ovarian cancer.
- Published
- 1998
5. Options for state chemicals policy reform:A resource guide
- Author
-
Denison, R., Hansen, Steffen Foss, Geiser, K., Kyle, A., Massey, R., McPherson, A., Rejeski, D., Rossi, M., and Tickner, J.
- Published
- 2008
6. Iniciando programas de Producción más Limpia y Prevención de la Contaminación
- Author
-
Baas, LW, Geiser, K, Huisingh, D, Velazquez, L, University Hermosillo, Sonora, and Erasmus School of Social and Behavioural Sciences
- Published
- 2002
7. ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
- Author
-
Parmar, M, Torri, V, Bonaventura, A, Bonazzi, C, Colombo, N, Delaloye, J, Marsoni, S, Mangioni, C, Sandercock, J, Sessa, C, Williams, C, Tinazzi, A, Flann, M, Geiser, K, Scorpiglione, N, Stewart, J, Chaves, J, Palmeiro, E, Curtain, A, Mccormack, T, Gennatas, C, Marras, F, Oppo, T, Balestrino, M, Malzoni, C, Malzoni, M, Belli, M, Geminiani, M, Crestani, G, Monaco, A, Vavala, V, Piatto, E, Barattini, G, Fornara, P, Chetri, M, Santeufemia, G, Artioli, F, Carone, D, Fanizza, G, Trentadue, R, Priolo, D, Scollo, P, Nigro, S, Petrina, M, Mastrantonio, P, Spanna, G, Zagni, R, Belloni, C, Colleoni, R, Redaelli, L, Cavagnini, A, Di Costanzo, G, Perroni, D, Arienti, S, Orfanotti, G, Cantoni, F, Secli, R, Bianchi, A, Martinello, R, Mollica, G, Maizzi, D, Picchiarelli, M, Fiorini, G, Borsani, M, Colombo, E, Garsia, S, Melgrati, L, Paggi, G, Brunenghi, G, Casini, M, Isa, L, Algeri, R, Prozio, G, Belfiore, G, Angelini, F, D'Aprile, M, Moreschi, M, Mauri, M, Natale, N, Senzani, F, Pavanato, G, Poggi, G, Garuti, G, Luerti, M, Cruciani, G, Pagano, F, Baccolo, M, Poddi, E, Bocciolone, L, Sabelli, M, Maggi, R, Restelli, C, D'Antona, A, Locatelli, M, Pessi, A, Raina, A, Chiari, S, Gabriele, A, Pittelli, M, Iacobelli, P, Dogliotti, L, Gorzegno, G, Musso, P, Vegna, G, Coco, G, Alletti, D, Picciotto, F, Lucchese, V, Epis, A, di Palumbo, V, Drudi, G, Ravaioli, A, Zampella, D, Morandi, M, Gorga, G, Zucchelli, C, Cariello, S, Galletto, L, Sussio, M, Massacesi, L, Massacesi, M, Carli, A, Tucci, E, Tajani, E, Corrado, G, Bumma, S, Durando, A, Massobrio, M, Sberveglieri, M, Biasio, M, Guercio, E, Jura, R, Danese, S, Wierdis, T, Farnelli, C, Tarantino, G, Grassi, R, Repetti, F, Rocchi, B, Grampa, M, Ercoli, A, Griso, C, Signori, E, Zanini, L, Presti, M, Klimek, M, Urbanski, K, Biswas, A, Viegas, O, Kochli, O, Dreher, E, Fey, M, Beck, G, Ludin, J, Bonnefoi, H, Krauer, F, Bauer, J, Delmore, G, Furrer, C, Lorenz, U, Thurlimann, B, Bronz, L, Sanna, P, Wyss, D, Goldhirsch, A, Gyr, T, Leidi, L, Pastorelli, G, Pagani, O, Rey, P, Hailer, U, Benz, J, Kaye, S, Reed, N, Symonds, R, Atkinson, R, Axford, A, Rustin, G, Seckl, M, Green, J, Scott, I, Guthrie, D, Harper, P, Calman, F, Dobbs, H, Weir, P, Cassoni, A, Lederman, J, Souhami, R, Bozzino, J, Adab, F, Redman, C, Scoble, J, Paterson, M, Daniel, F, Cowley, N, Spooner, D, Hong, A, Mcillmurray, M, Hendy Ibbs, P, Hall, V, Iveson, T, Whitehouse, J, Garry, R, Lamont, A, Robinson, A, Trask, C, Clubb, A, Murrell, D, Newman, G, Wilkins, M, Goldthorp, W, Roberts, J, Radstone, D, Whipp, M, Ledermann, J, Pater, J, Buyse, M, Omura, G, Parmar, MKB, McCormack, T, McIllmurray, M, Omura, G., COLOMBO, NICOLETTA, Parmar, M, Torri, V, Bonaventura, A, Bonazzi, C, Colombo, N, Delaloye, J, Marsoni, S, Mangioni, C, Sandercock, J, Sessa, C, Williams, C, Tinazzi, A, Flann, M, Geiser, K, Scorpiglione, N, Stewart, J, Chaves, J, Palmeiro, E, Curtain, A, Mccormack, T, Gennatas, C, Marras, F, Oppo, T, Balestrino, M, Malzoni, C, Malzoni, M, Belli, M, Geminiani, M, Crestani, G, Monaco, A, Vavala, V, Piatto, E, Barattini, G, Fornara, P, Chetri, M, Santeufemia, G, Artioli, F, Carone, D, Fanizza, G, Trentadue, R, Priolo, D, Scollo, P, Nigro, S, Petrina, M, Mastrantonio, P, Spanna, G, Zagni, R, Belloni, C, Colleoni, R, Redaelli, L, Cavagnini, A, Di Costanzo, G, Perroni, D, Arienti, S, Orfanotti, G, Cantoni, F, Secli, R, Bianchi, A, Martinello, R, Mollica, G, Maizzi, D, Picchiarelli, M, Fiorini, G, Borsani, M, Colombo, E, Garsia, S, Melgrati, L, Paggi, G, Brunenghi, G, Casini, M, Isa, L, Algeri, R, Prozio, G, Belfiore, G, Angelini, F, D'Aprile, M, Moreschi, M, Mauri, M, Natale, N, Senzani, F, Pavanato, G, Poggi, G, Garuti, G, Luerti, M, Cruciani, G, Pagano, F, Baccolo, M, Poddi, E, Bocciolone, L, Sabelli, M, Maggi, R, Restelli, C, D'Antona, A, Locatelli, M, Pessi, A, Raina, A, Chiari, S, Gabriele, A, Pittelli, M, Iacobelli, P, Dogliotti, L, Gorzegno, G, Musso, P, Vegna, G, Coco, G, Alletti, D, Picciotto, F, Lucchese, V, Epis, A, di Palumbo, V, Drudi, G, Ravaioli, A, Zampella, D, Morandi, M, Gorga, G, Zucchelli, C, Cariello, S, Galletto, L, Sussio, M, Massacesi, L, Massacesi, M, Carli, A, Tucci, E, Tajani, E, Corrado, G, Bumma, S, Durando, A, Massobrio, M, Sberveglieri, M, Biasio, M, Guercio, E, Jura, R, Danese, S, Wierdis, T, Farnelli, C, Tarantino, G, Grassi, R, Repetti, F, Rocchi, B, Grampa, M, Ercoli, A, Griso, C, Signori, E, Zanini, L, Presti, M, Klimek, M, Urbanski, K, Biswas, A, Viegas, O, Kochli, O, Dreher, E, Fey, M, Beck, G, Ludin, J, Bonnefoi, H, Krauer, F, Bauer, J, Delmore, G, Furrer, C, Lorenz, U, Thurlimann, B, Bronz, L, Sanna, P, Wyss, D, Goldhirsch, A, Gyr, T, Leidi, L, Pastorelli, G, Pagani, O, Rey, P, Hailer, U, Benz, J, Kaye, S, Reed, N, Symonds, R, Atkinson, R, Axford, A, Rustin, G, Seckl, M, Green, J, Scott, I, Guthrie, D, Harper, P, Calman, F, Dobbs, H, Weir, P, Cassoni, A, Lederman, J, Souhami, R, Bozzino, J, Adab, F, Redman, C, Scoble, J, Paterson, M, Daniel, F, Cowley, N, Spooner, D, Hong, A, Mcillmurray, M, Hendy Ibbs, P, Hall, V, Iveson, T, Whitehouse, J, Garry, R, Lamont, A, Robinson, A, Trask, C, Clubb, A, Murrell, D, Newman, G, Wilkins, M, Goldthorp, W, Roberts, J, Radstone, D, Whipp, M, Ledermann, J, Pater, J, Buyse, M, Omura, G, Parmar, MKB, McCormack, T, McIllmurray, M, Omura, G., and COLOMBO, NICOLETTA
- Abstract
A series of meta-analyses of randomised controlled trials raised the question of whether the three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) was more or less effective than optimal-dose single-agent carboplatin for women with advanced ovarian cancer.
- Published
- 1998
8. Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia
- Author
-
De Botton, S., primary, Dombret, H., additional, Sanz, M., additional, Miguel, J. San, additional, Caillot, D., additional, Zittoun, R., additional, Gardembas, M., additional, Stamatoulas, A., additional, Condé, E., additional, Guerci, A., additional, Gardin, C., additional, Geiser, K., additional, Makhoul, D. Cony, additional, Reman, O., additional, de la Serna, J., additional, Lefrere, F., additional, Chomienne, C., additional, Chastang, C., additional, Degos, L., additional, Fenaux, P., additional, and Group, the European APL, additional
- Published
- 1998
- Full Text
- View/download PDF
9. Protecting reproductive health and the environment: toxics use reduction.
- Author
-
Geiser, K, primary
- Published
- 1993
- Full Text
- View/download PDF
10. The problem of current toxic chemicals management.
- Author
-
Tickner J and Geiser K
- Abstract
In this article, we explore the limitations of current chemicals management policies worldwide and the evolution of new European, International and U.S. policies to address the problem of toxic chemicals control. It is becoming increasingly apparent that current chemicals management policies in Europe and the United States are inadequate. There is a general lack of toxicity and exposure information on chemicals in commerce and the vast majority of chemicals were considered safe until proven guilty in legislation. Governments must then prove each chemical is dangerous through a slow and resource-intensive risk assessment process. For more than a decade, Nordic countries, such as Denmark and Sweden, have actively promoted integrated chemicals policies to address contamination of critical waterways. They have successfully used a variety of voluntary and mandatory policy tools, such as education, procurement, lists of chemicals of concern, eco-labeling, research and development on safer substitutes, and chemical phase-out requirements, to encourage companies using chemicals to reduce their reliance on harmful substances and to develop safer substitutes. While previously isolated to particular countries, innovative and exciting European-wide policies to promote sustainable chemicals management are now moving forward, including the recently published draft Registration, Evaluation and Authorization of CHemicals (REACH) policy of the European Union. A sweeping change in chemicals management policies in Europe is inevitable and it will ultimately affect manufacturers in the U.S. and globally. The European movement provides an opportunity to initiate a discussion on integrated chemicals policy in the U.S. where some innovative initiatives already are underway. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
11. Nanotechnology and environmental and public health considerations.
- Author
-
Geiser K
- Abstract
Nanotechnology has arrived on the scene much as did predecessor technologies--hailed for its purpose and accepted with enthusiasm amid bursts of research, funding, and news of creative applications. But the early efforts to consider its environmental aspects have been small even though the implications for environmental and public health are broad. A well-crafted policy framework is needed, one linked to a clearer understanding of the direct and indirect effects, benefits, and risk of nanotechnology. A precautious approach would foster policy interventions to prevent harms by slowing developments where the risks are high and focus scientific effort on dispelling ignorance and uncertainty, especially in those areas where the consequences of being wrong are substantial. This kind of approach also would impose the burden of demonstrating the safety of the technology primarily on its proponents. The process of producing guidelines for other technologies is considered. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
12. In remembrance: John O'Connor: 'knew how to link hope and vision to the issues'.
- Author
-
Geiser K and Wilson R
- Published
- 2002
13. The greening of industry.
- Author
-
Geiser, K.
- Subjects
- *
ENVIRONMENTAL policy - Abstract
Observes a growing international consensus around the need to reconsider conventional approaches to environmental regulation of industry. Overview of the concept of sustainability; How it addresses the shortcomings and failures of 25 years of pollution control regulations; How states are taking the lead in the transition to pollution prevention; Move toward clean technology; International trend toward sustainable industry. INSET: Techniques for reducing toxics use..
- Published
- 1991
14. Totentanz-Nachklänge
- Author
-
Geiser, K.
- Published
- 1906
- Full Text
- View/download PDF
15. Aus den Lehrjahren eines Berner Patriziers zur Zeit der Mediation
- Author
-
Geiser, K.
- Published
- 1912
- Full Text
- View/download PDF
16. Ein Nagel-neues Lied von denen Fahnen und Farben des Teutschen Bärn-Gebieths
- Author
-
Geiser, K.
- Published
- 1896
- Full Text
- View/download PDF
17. Erlebnisse eines bernischen Dragoner-Lieutenants in den Märztagen 1798
- Author
-
Geiser, K.
- Published
- 1898
- Full Text
- View/download PDF
18. Ein bernisches Pfarrhaus in den Märztagen 1798 : nach einem Tagebuch von Pfarrer J. Müller in Limpach
- Author
-
Geiser, K.
- Published
- 1891
- Full Text
- View/download PDF
19. Materials matter: towards a sustainable materials policy.
- Author
-
Geiser K. and Geiser K.
20. The search for safer and greener chemical solvents in surface cleaning: a proposed tool to support environmental decision-making
- Author
-
Leblanc, CA, Huisingh, D, Geiser, K, and Erasmus School of Social and Behavioural Sciences
- Published
- 2001
21. Clinical and laboratory genetic counseling assistants: Comparing background experiences, responsibilities, satisfaction, and career goals.
- Author
-
Gagne C, Geiser K, Danylchuk NR, Jin J, and McWalter K
- Abstract
Understanding the responsibilities, qualifications, future plans, and contributions of genetic counseling assistants (GCAs) across all work settings could aid in establishing a scope of practice, advocating for creation of GCA positions, and informing future education and training for GCAs and genetic counselors. We compared laboratory and clinical GCA responsibilities, sources of job satisfaction, background experience, and career goals. Sixty-five laboratory and 73 clinical GCAs participated in this study by completing an online survey. Most participants had a Bachelor of Science/Arts and aspired to become genetic counselors (GCs). Clinical GCAs had more interaction with patients, whereas laboratory GCAs had more interaction with ordering providers and little to no patient contact. On a scale from 0 (not at all satisfied) to 10 (extremely satisfied), clinical GCAs had statistically significant higher satisfaction ratings (M = 8.56, SD = 1.42) than laboratory GCAs (M = 7.35, SD = 1.82, U = 3346, p = 0.001). While most participants were GCAs for 13-18 months, laboratory GCAs stayed in their positions (19-24 months, n = 20, 30.8%) for significantly longer than clinical GCAs (7-12 months, n = 21, 28.8%, X
2 (5) = 12.799, p = 0.025). GCAs noted increases in their knowledge and new skill development, though we also identified responsibilities for which they did not feel qualified. The results of this study can potentially help define a GCA scope of practice with data regarding background experiences and responsibilities. In addition, GCA employers may use the results to retain GCAs by addressing satisfaction issues, providing appropriate training, and adjusting roles. GC training program directors can use the results to manage expectations of applicants with GCA experience and inform training and curriculum needs based on the composition of a GC class., (© 2023 National Society of Genetic Counselors.)- Published
- 2023
- Full Text
- View/download PDF
22. Taking the Climate Crisis Personally.
- Author
-
Geiser K
- Subjects
- Humans, Climate Change, Democracy
- Published
- 2020
- Full Text
- View/download PDF
23. High-velocity micro-particle impact on gelatin and synthetic hydrogel.
- Author
-
Veysset D, Kooi SE, Мaznev AA, Tang S, Mijailovic AS, Yang YJ, Geiser K, Van Vliet KJ, Olsen BD, and Nelson KA
- Subjects
- Gelatin chemistry, Hydrogels chemistry, Microspheres
- Abstract
The high-velocity impact response of gelatin and synthetic hydrogel samples is investigated using a laser-based microballistic platform for launching and imaging supersonic micro-particles. The micro-particles are monitored during impact and penetration into the gels using a high-speed multi-frame camera that can record up to 16 images with nanosecond time resolution. The trajectories are compared with a Poncelet model for particle penetration, demonstrating good agreement between experiments and the model for impact in gelatin. The model is further validated on a synthetic hydrogel and the applicability of the results is discussed. We find the strength resistance parameter in the Poncelet model to be two orders of magnitude higher than in macroscopic experiments at comparable impact velocities. The results open prospects for testing high-rate behavior of soft materials on the microscale and for guiding the design of drug delivery methods using accelerated microparticles., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
24. The Architecture of Chemical Alternatives Assessment.
- Author
-
Geiser K, Tickner J, Edwards S, and Rossi M
- Abstract
Chemical alternatives assessment is a method rapidly developing for use by businesses, governments, and nongovernment organizations seeking to substitute chemicals of concern in production processes and products. Chemical alternatives assessment is defined as a process for identifying, comparing, and selecting safer alternatives to chemicals of concern (including those in materials, processes, or technologies) on the basis of their hazards, performance, and economic viability. The process is intended to provide guidance for assuring that chemicals of concern are replaced with safer alternatives that are not likely to be later regretted. Conceptually, the assessment methods are developed from a set of three foundational pillars and five common principles. Based on a number of emerging alternatives assessment initiatives, in this commentary, we outline a chemical alternatives assessment blueprint structured around three broad steps: Scope, Assessment, and Selection and Implementation. Specific tasks and tools are identified for each of these three steps. While it is recognized that on-going practice will further refine and develop the method and tools, it is important that the structure of the assessment process remain flexible, adaptive, and focused on the substitution of chemicals of concern with safer alternatives., (© 2015 Society for Risk Analysis.)
- Published
- 2015
- Full Text
- View/download PDF
25. Are green building features safe for preventive maintenance workers? Examining the evidence.
- Author
-
Omar MS, Quinn MM, Buchholz B, and Geiser K
- Subjects
- Humans, Risk Assessment, United States, Facility Design and Construction standards, Maintenance, Occupational Health, Safety Management organization & administration
- Abstract
Background: Many newly constructed green buildings (GB) are certified using the United States Green Building Council (USGBC) Leadership in Energy and Environmental Design (LEED) rating system for new construction and major renovation which focuses on architectural and mechanical design to conserve energy, reduce environmental harm, and enhance indoor quality for occupants. This study evaluated the preventive maintenance (PM) worker occupational safety and health (OSH) risks related to the design of GB., Methods: PM job hazard analyses (JHA) were performed on the tasks required to operate and maintain five GB features selected from 13 LEED certified GB. A 22-item JHA and OSH risk scoring system were developed., Results: Potentially serious OSH hazards included: green roofs made of slippery material without fall protection; energy recovery wheels and storm water harvesting systems in confined spaces; skylights without guard rails; and tight geothermal well mechanical rooms constraining safe preventive practices., Conclusions: GB can present PM OSH risks and these should be eliminated in the building design phase., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
26. The dilemma of promoting green products: what we know and don't know about biobased metalworking fluids.
- Author
-
Massawe E and Geiser K
- Subjects
- Metallurgy, Organic Chemicals analysis, Organic Chemicals classification, Petroleum analysis, Public Health, Surveys and Questionnaires, United States, Environmental Health, Green Chemistry Technology, Industrial Oils analysis, Industrial Oils classification
- Abstract
Advocates of "green products" argue that promoting these products can protect the environment, workers, and public health. Biobased metalworking fluids (MWFs) are among the products promoted as "green products." The main question is, what constitutes a green product? To answer this question, the authors compared and contrasted the health and safety aspects of biobased and petroleum-based MWFs in terms of their additives. These two product categories of MWFs derived from various feedstocks were investigated through interviews and literature review. Three classes of biobased MWFs and four classes of petroleum-based MWFs were identified and compared. The little information available on the individual constituents for biobased MWFs indicates that they had biocides and preservatives, corrosion inhibitors, extreme pressure, and antiwear components, which are also common additives in petroleum-based MWFs. Precautionary approaches should be taken when promoting biobased MWFs as "green products" until individual components are evaluated for their health and safety impacts.
- Published
- 2012
27. How developing nations can protect children from hazardous chemical exposures while sustaining economic growth.
- Author
-
Trasande L, Massey RI, DiGangi J, Geiser K, Olanipekun AI, and Gallagher L
- Subjects
- Child, Environmental Monitoring, Food Contamination, Health Policy, Humans, Vulnerable Populations, Waste Management, Developing Countries, Economic Development, Environmental Exposure adverse effects, Environmental Exposure prevention & control, Hazardous Substances toxicity
- Abstract
Increasing worldwide use of chemicals, including heavy metals used in industry and pesticides used in agriculture, may produce increases in chronic diseases in children unless steps are taken to manage the production, use, trade, and disposal of chemicals. In 2020 the developing world will account for 33 percent of global chemical demand and 31 percent of production, compared with 23 percent and 21 percent, respectively, in 1995. We describe present and potential costs of environmental exposures and discuss policy options to protect future generations of children in a sustainable development context. Specifically, we describe the principles of sound chemicals management, as follows: precaution, or the use of cost-effective measures to prevent potentially hazardous exposures before scientific understanding is complete; the right to know, or informing the public--especially vulnerable groups--in a timely fashion about the safe use of chemicals and any releases of chemicals into the environment; pollution prevention, or preventing the use of hazardous chemicals and the production of pollutants, rather than focusing on managing wastes; internalization of environmental and health costs, or ensuring that the consequences of exposures are reflected in the price of chemicals through such approaches as "polluter pays"; and use of best available scientific information in making decisions such as what chemicals to allow into the market. We recommend that industrializing nations in particular employ these principles to prevent disease among their populations while at the same time minimizing the risk to their own economic development.
- Published
- 2011
- Full Text
- View/download PDF
28. Redesigning chemicals policy: a very different approach.
- Author
-
Geiser K
- Subjects
- Government Regulation, Public Health, Public Policy legislation & jurisprudence, Safety, United States, Hazardous Substances, Policy Making
- Abstract
The chemical policies of the 1970s were limited by the assumptions that lie at their foundation and focused narrowly on only the most hazardous chemicals. The effective management of chemicals requires policies that focus on the entire body of chemicals and the production systems that make them. The future will require comprehensive chemicals policies that work within a systems framework to phase out the most hazardous chemicals, progressively transition away from the remaining chemicals of concern by substituting safer chemicals and technologies, and invest heavily in a new generation of safer and more sustainable chemicals.
- Published
- 2011
- Full Text
- View/download PDF
29. Reforming state-level chemicals management policies in the United States: status, challenges, and opportunities.
- Author
-
Geiser K, Tickner J, and Torrie Y
- Subjects
- Chemical Industry standards, Conservation of Natural Resources, Environment, Europe, Humans, State Government, United States, Chemical Industry organization & administration, Environmental Pollutants standards, Environmental Pollution prevention & control, Hazardous Substances standards, Policy Making
- Abstract
During the last several years there has been increasing public concern about chemicals in everyday products. Scientific studies are increasingly revealing the build-up of some substances in ecosystems and in our bodies and new findings are linking exposures to hazardous chemicals to a range of adverse human health effects. Despite these trends, there has been little federal initiative in the United States on reforming chemicals management policies for well over two decades, even though a variety of analyses have identified significant gaps in the regulatory structure. As has historically been the case, states are beginning to fill the holes in federal leadership. This article explores this emerging state leadership and establishes a vision for and elements of policies to reduce hazardous chemicals in the products we buy and the places we go. It examines international efforts to reform chemicals management policies, such as the European REACH legislation and corporate leadership in advancing safer products. Finally, it outlines specific challenges states face in developing integrated, comprehensive chemicals management policies. We conclude that while there are plenty of challenges to implementation of chemicals policy reforms, it is a propitious time for states to become leaders in policy innovation that can help achieve safer production systems and products for future generations. This article is part of a Lowell Center for Sustainable Production report entitled "Options for State Chemicals Policy Reform" that provides in-depth analysis of the pros and cons of policy options to address a range of aspects of state-level chemicals policy reform. The article has been edited slightly for use in New Solutions. The report has been widely distributed to policy-makers, advocates, and others across the United States.
- Published
- 2009
- Full Text
- View/download PDF
30. Health, safety, and ecological implications of using biobased floor-stripping products.
- Author
-
Massawe E, Geiser K, Ellenbecker M, and Marshall J
- Subjects
- Costs and Cost Analysis, Massachusetts, Organic Chemicals, Detergents chemistry, Environmental Health, Floors and Floorcoverings, Household Products, Safety
- Abstract
The main objective of the study reported here was to investigate the ecological, health, and safety (EHS) implications of using biobased floor strippers as alternatives to solvent-based products such as Johnson Wax Professional (Pro Strip). The authors applied a quick EHS-scoring technique developed by the Surface Solution Laboratory (SSL) of the Toxics Use Reduction Institute (TURI) to some alternative, biobased products that had previously performed as well as or close to as well as the currently used product. The quick technique is considered an important step in EHS assessment, particularly for toxics use reduction planners and advocates who may not have the resources to subject many alternative products or processes at once to detailed EHS analysis. Taking this step narrows available options to a manageable number. (Technical-performance experiments were also conducted, but the results are not discussed or reported in this paper). The cost of switching to biobased floor strippers was assessed and compared with the cost of using the traditional product, both at full strength and at the dilution ratios recommended by the respective manufacturers. The EHS analysis was based on a framework consisting of five parameters: volatile organic compounds (VOCs); pH; global-warming potential (GWP); ozone depletion potential (ODP); and safety scores in areas such as flammability, stability, and special hazards, based on ratings from the Hazardous Material Classification System (HMIS) and the National Fire Protection Association (NFPA). Total EHS scores were calculated with data derived from the material safety data sheets. For most cleaning products previously investigated by the TURI SSL, the investigators have demonstrated that the five key parameters used in the study reported here can successfully be used for quick screening of the EHS impacts of cleaning alternatives. All eight biobased, or green, products evaluated in the study had better EHS-screening scores than did Pro Strip. One product, Botanic Gold, had a screening score of 49 out of a possible 50. This score was much higher than the score of 26 achieved by Pro Strip. The other biobased floor strippers had EHS-screening scores of > or =37, which is the average value of solvent-based cleaning solutions. These results indicate that biobased cleaning products capable of floor stripping are potentially better than traditional products with respect to the five EHS parameters used. The cost of switching to biobased floor strippers at their full strength ranged from a minimum of U.S. $15.50 per gallon ($4.10 per liter) for Eco Natural Floor Stripper (WPR) to about $59.00 per gallon ($15.61 per liter) for Botanic Gold. At 25 percent volume by volume (v/v), the recommended dilution ratio for the traditional product, the cost of the Botanic Gold was $14.75 per gallon ($3.90 per liter), or about five times more than that of Pro Strip, which was $2.48 per gallon ($0.65 per liter). Since these figures do not reflect all of the EHS costs, such as disposal and recycling fees, it is likely that use of Botanic Gold could be cost-effective in the long run. The authors therefore recommend that detailed EHS analysis be conducted on this alternative biobased floor stripper. It is also recommended that large field trials be conducted and that janitors' or consumers' perceptions be determined. For detailed assessment of eco-toxicological properties of the biobased floor strippers, investigations of the common additives in the Botanic Gold formulation should be conducted through use of databases on the World Wide Web such as Toxnet. Finally, the current policies, regulations, and standards that promote biobased products should be investigated to determine their strengths and weaknesses. This would encourage a broader public debate about the future of the biobased industry in the context of sustainability.
- Published
- 2007
31. The Louisville Charter: The NGO blueprint for new chemicals policy.
- Author
-
Geiser K, Rossi M, and Crumbley C
- Subjects
- Chemical Industry legislation & jurisprudence, Congresses as Topic, Hazardous Substances, Humans, Kentucky, Chemistry legislation & jurisprudence, Environmental Health, International Cooperation, Organizations, Policy Making
- Published
- 2007
- Full Text
- View/download PDF
32. Occupational safety and health in china, part I: u.s.-China symposium on "integrating occupational and environmental health".
- Author
-
Quinn M, Geiser K, and Lin L
- Abstract
A joint China-U.S. symposium entitled "Integrating Occupational and Environmental Health" was organized by the Department of Science and Technology of Hebei Province, PRC, and the Department of Work Environment at the University of Massachusetts Lowell, U.S.A. A framework called "Sustainable Production" was proposed by U.S. participants to link environmental and worker protection. Sustainable production focuses on systems of production that integrate concerns for the long-term viability of the environment, worker health and safety, the community, and the economic performance of firms and other enterprises. The disciplines of environmental and occupational health and safety were brought together by Chinese participants under the unifying theme of the development, implementation, and impact of new technologies. As production processes are increasingly concentrated in China, collaboration among U.S. and Chinese environmental and occupational health and safety professionals is ever more essential.
- Published
- 2005
- Full Text
- View/download PDF
33. The U.S. experience in promoting sustainable chemistry.
- Author
-
Tickner JA, Geiser K, and Coffin M
- Subjects
- Data Collection, Federal Government, Humans, Policy Making, Risk Assessment, State Government, United States, Chemical Industry, Conservation of Natural Resources, Environment, Environmental Pollution prevention & control
- Abstract
Background, Aim and Scope: Recent developments in European chemicals policy, including the Registration, Evaluation and Authorization of Chemicals (REACH) proposal, provide a unique opportunity to examine the U.S. experience in promoting sustainable chemistry as well as the strengths and weaknesses of existing policies. Indeed, the problems of industrial chemicals and limitations in current regulatory approaches to address chemical risks are strikingly similar on both sides of the Atlantic. We provide an overview of the U.S. regulatory system for chemicals management and its relationship to efforts promoting sustainable chemistry. We examine federal and state initiatives and examine lessons learned from this system that can be applied to developing more integrated, sustainable approaches to chemicals management., Main Features: There is truly no one U.S. chemicals policy, but rather a series of different un-integrated policies at the federal, regional, state and local levels. While centerpiece U.S. Chemicals Policy, the Toxic Substances Control Act of 1976, has resulted in the development of a comprehensive, efficient rapid screening process for new chemicals, agency action to manage existing chemicals has been very limited. The agency, however, has engaged in a number of successful, though highly underfunded, voluntary data collection, pollution prevention, and sustainable design programs that have been important motivators for sustainable chemistry. Policy innovation in the establishment of numerous state level initiatives on persistent and bioaccumulative toxics, chemical restrictions and toxics use reduction have resulted in pressure on the federal government to augment its efforts., Results and Conclusions: It is clear that data collection on chemical risks and phase-outs of the most egregious chemicals alone will not achieve the goals of sustainable chemistry. These alone will also not internalize the cultural and institutional changes needed to ensure that design and implementation of safer chemicals, processes, and products are the focus of the future. Thus, a more holistic approach of 'carrots and sticks'--that involves not just chemical producers but those who use and purchase chemicals is necessary. Some important lessons of the US experience in chemicals management include: (1) the need for good information on chemicals flows, toxic risks, and safer substances.; (2) the need for comprehensive planning processes for chemical substitution and reduction to avoid risk trade-offs and ensure product quality; (3) the need for technical and research support to firms for innovation in safer chemistry; and (4) the need for rapid screening processes and tools for comparison of alternative chemicals, materials, and products.
- Published
- 2005
- Full Text
- View/download PDF
34. Joint occupational and environmental pollution prevention strategies: a model for primary prevention.
- Author
-
Armenti K, Moure-Eraso R, Slatin C, and Geiser K
- Abstract
Occupational and environmental health issues are not always considered simultaneously when attempting to reduce or eliminate hazardous materials from our environment. Methods used to decrease exposure to hazardous chemicals in the workplace often lead to increased exposure in the environment and to the community outside the workplace. Conversely, efforts to control emissions of hazardous chemicals into the environment often lead to increased exposure to the workers inside the plant. There are government regulations in place that ensure a safe work environment or a safe outside environment; however, there is little integration of both approaches when considering the public's health as a whole. This article examines some of the reasons behind this dichotomy, focusing on the regulatory and policy frameworks with respect to workplace and environment that have resulted in the inability of the Occupational Safety and Health Administration (OSHA) and the Environmental Protection Agency (EPA) to coordinate their efforts to protect public health. The components of the Pollution Prevention Act and its potential to serve as a model for integrating occupational and environmental health are discussed. Limitations regarding enforcement of pollution prevention, as well as its disconnection from the work environment are equally highlighted. The article finishes by examining the barriers to integrating the occupational and environmental health paradigms and the promotion of primary prevention in public health.
- Published
- 2003
- Full Text
- View/download PDF
35. Making materials matter.
- Author
-
Geiser K
- Abstract
For sustainability, it would be much more effective and economically efficient to focus on designing and using less hazardous materials. By paying more attention to the materials that we manufacture and use, we could pay less attention to their impacts on people and the environment. The environmental costs of materials show up in damage from materials extraction, pollution, energy consumed, and waste material disposal. The model on which the materials management system is based is flawed. Future systems must be cyclical ones of sustainable managed material flows that conserve resources and minimize dissipation. Material recycling and reuse must be primary components, along with new extraction, harvesting, and treatment practices. Needed are new policies that promote human health and environmental quality, as well as economic efficiency and product effectiveness. The policies may be either public or private, but they must be integrative and focused on the full life cycle of materials. This sustainable materials economy will require new information systems, re-direction of materials markets, reconfiguration of corporate missions and designs, changes in government policies, and public engagement.
- Published
- 2002
- Full Text
- View/download PDF
36. Why promote campaigns for clean products and clean production?
- Author
-
Geiser K
- Abstract
Environmental advocacy in the United States has focused on controlling pollution and waste through a system based on government permits for managing the release of environmental pollutants. The conventional focus on pollution control and waste management has been less than comprehensive. From an ecological perspective it makes little sense to focus on reducing environmental pollution from the waste pipe of industrial facilities while ignoring those same pollutants when inside the plant or sent out the product door. But an ecological perspective is not the same as a political perspective. The focus on pollution and waste has achieved legitimacy; focusing on production appears to invite an invasion of private property, a sensitive issue for most businesses. Discussing the constituents and volume of products treads on issues many think should best be reserved for the market. Focusing on production and products requires technical knowledge and skills not conventionally found in environmental advocacy organizations. Why should environmental or occupational health advocates stretch their conventional domain? Here is an argument for products and production, listing ten reasons for campaigning on clean production and products.
- Published
- 1999
- Full Text
- View/download PDF
37. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.
- Author
-
De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, Gardembas M, Stamatoulas A, Condé E, Guerci A, Gardin C, Geiser K, Makhoul DC, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, and Fenaux P
- Subjects
- Acute Kidney Injury chemically induced, Adult, Aged, Antibiotics, Antineoplastic administration & dosage, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cardiovascular Diseases chemically induced, Cytarabine administration & dosage, Dexamethasone therapeutic use, Disease-Free Survival, Female, Humans, Incidence, Leukocyte Count drug effects, Life Tables, Male, Middle Aged, Pericardial Effusion chemically induced, Pleural Effusion chemically induced, Proportional Hazards Models, Remission Induction, Respiration Disorders chemically induced, Survival Rate, Syndrome, Treatment Outcome, Tretinoin therapeutic use, Antineoplastic Agents adverse effects, Leukemia, Promyelocytic, Acute drug therapy, Tretinoin adverse effects
- Abstract
All trans-retinoic acid (ATRA) syndrome is a life-threatening complication of uncertain pathogenesis that can occur during the treatment of acute promyelocytic leukemia (APL) by ATRA. Since its initial description, however, no large series of ATRA syndrome has been reported in detail. We analyzed cases of ATRA syndrome observed in an ongoing European trial of treatment of newly diagnosed APL. In this trial, patients 65 years of age or less with an initial white blood cell count (WBC) less than 5,000/microL were initially randomized between ATRA followed by chemotherapy (CT) (ATRA-->CT group) or ATRA with CT started on day 3; patients with WBC greater than 5,000/microL received ATRA and CT from day 1; patients aged 66 to 75 received ATRA-->CT. In patients with initial WBC less than 5, 000/microL and allocated to ATRA-->CT, CT was rapidly added if WBC was greater than 6,000, 10,000, 15,000/microL by days 5, 10, and 15 of ATRA treatment. A total of 64 (15%) of the 413 patients included in this trial experienced ATRA syndrome during induction treatment. Clinical signs developed after a median of 7 days (range, 0 to 35 days). In two of them, they were in fact present before the onset of ATRA. In 11 patients, they occurred upon recovery from the phase of aplasia due to the addition of CT. Respiratory distress (89% of the patients), fever (81%), pulmonary infiltrates (81%), weight gain (50%), pleural effusion (47%), renal failure (39%), pericardial effusion (19%), cardiac failure (17%), and hypotension (12%) were the main clinical signs, and 63 of the 64 patients had at least three of them. Thirteen patients required mechanical ventilation and two dialysis. A total of 60 patients received CT in addition to ATRA as per protocol or based on increasing WBC; 58 also received high dose dexamethasone (DXM); ATRA was stopped when clinical signs developed in 30 patients. A total of 55 patients (86%) who experienced ATRA syndrome achieved complete remission (CR), as compared with 94% of patients who had no ATRA syndrome (P = .07) and nine (14%) died of ATRA syndrome (5 cases), sepsis (2 cases), leukemic resistance (1 patient), and central nervous system (CNS) bleeding (1 patient). None of the patients who achieved CR and received ATRA for maintenance had ATRA syndrome recurrence. No significant predictive factors of ATRA syndrome, including pretreatment WBC, could be found. Kaplan Meier estimates of relapse, event-free survival (EFS), and survival at 2 years were 32% +/- 10%, 63% +/- 8%, and 68% +/- 7% in patients who had ATRA syndrome as compared with 15% +/- 3%, 77% +/- 2%, and 80% +/- 2% in patients who had no ATRA syndrome (P = .05, P = .003, and P = .03), respectively. In a stepwise Cox model that also included pretreatment prognostic variables, ATRA syndrome remained predictive for EFS and survival. In conclusion, in this multicenter trial where CT was rapidly added to ATRA in case of high or increasing WBC counts and DXM generally also used at the earliest clinical sign, the incidence of ATRA syndrome was 15%, but ATRA syndrome was responsible for death in only 1.2% of the total number of patients treated. However, occurrence of ATRA syndrome was associated with lower EFS and survival., (Copyright 1998 by The American Society of Hematology.)
- Published
- 1998
38. Sustainable production: a proposed strategy for the work environment.
- Author
-
Quinn MM, Kriebel D, Geiser K, and Moure-Eraso R
- Subjects
- Economic Competition, Forecasting, Humans, Occupational Exposure standards, United States, Workplace, Environmental Monitoring standards, Environmental Pollution prevention & control, Occupational Exposure prevention & control, Occupational Health
- Abstract
Background: In the future, competitive industries will need to design for environment, health and safety as well as for productivity. Although the new areas of pollution prevention and clean production have evolved to address the design of production processes with concerns for the ambient environment, current pollution prevention models do not include explicit concerns for health, safety, and the work environment. The field of occupational health and safety has much to contribute to improve current pollution prevention approaches and solutions., Methods: The application of work environment disciplines will need to be expanded from the conventional focus on "end-of-pipe" assessment and solutions, which take the production processes and resulting hazards as a given, to include a new focus on materials selection and process redesign. To make this shift, a new framework called "sustainable production" is proposed. The basic unit of sustainable production is the production process. The framework integrates a focus on the ambient and work environment along with a focus on productivity and the economic viability of the business enterprise in setting production process design parameters., Results: By shifting the focus of occupational and environmental health and safety from exposure control to process design, sustainable production reduces the likelihood that concerns for health, safety, and the environment will be seen as antagonistic to productivity and economic development. To move a firm toward sustainable production, occupational health and safety professionals will need to participate in interdisciplinary workplace teams that design and build new production processes and that continuously evaluate and redesign existing processes., Conclusions: This new strategy requires an expansion of the role of the occupational health and safety professional to include evaluation and redesign of processes that produce goods and services as well as the conventional evaluation of chemical, physical, and biological agents, work practices, and ergonomics. This expansion of occupational and environmental health and safety requires new research to develop the scientific and public policy basis of sustainable production.
- Published
- 1998
- Full Text
- View/download PDF
39. Peer reviewed: massachusetts tries to cut toxic chemicals use.
- Author
-
Becker M, Geiser K, and Keenan C
- Abstract
An evaluation of statewide effort reveals toxic chemical use and waste generation have declined.
- Published
- 1997
- Full Text
- View/download PDF
40. Techniques in toxics use reduction:.
- Author
-
Rossi M, Ellenbecker M, and Geiser K
- Published
- 1991
- Full Text
- View/download PDF
41. Toxics use reduction and pollution prevention.
- Author
-
Geiser K
- Published
- 1990
- Full Text
- View/download PDF
42. Health hazards in the microelectronics industry.
- Author
-
Geiser K
- Subjects
- Environmental Exposure, Humans, Occupational Diseases chemically induced, Occupational Diseases prevention & control, Risk, Safety, Electronics, Occupational Diseases etiology
- Abstract
The microelectronics industry is explored as a source of occupational health hazards resulting from the extensive use of toxic chemicals in the production of semiconductor chips and the assembly of electronic components. Information is provided on the range of chemicals used in the industry and their particular health implications. Case materials are drawn from Massachusetts' "Route 128" region and California's "Silicon Valley." Problems with worker exposure in the plants are compared with the risks experienced by residents of local neighborhoods from the leakage of industrial chemicals from underground storage tanks into the local groundwater used for drinking water. The recent development of the industry, its highly innovative character, the absence of unions and organizations for worker protection, and the persistence of a public perception that the industry is relatively safe and clean, are all identified as determinants of the extent of health hazards posed by chemical exposure. The paper concludes with recommendations for further studies, worker organization, and increased attention to the reduction of the volume and toxicity of chemicals in industrial production.
- Published
- 1986
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.